Men diagnosed with high-risk localized prostate cancer now have trial-level evidence that adding the drug apalutamide to ...

An enhanced telehealth model demonstrates feasibility and high clinician and patient acceptability for prostate cancer management.

I f prostate cancer has spread to other areas of your body, your doctor may recommend androgen deprivation therapy (ADT), which halts the production of androgen hormones, especially testosterone.

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of international research on androgen deprivation therapy (ADT) for prostate cancer ...

A study co-led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that most of the benefits of androgen deprivation therapy (ADT) for prostate cancer occur within the first ...

Men treated for prostate cancer after surgery now have clearer evidence that extending hormone therapy from six months to two ...

In a pooled analysis, longer duration of androgen deprivation therapy (ADT) was associated with nonlinear improvements in outcomes in men with prostate cancer receiving definitive radiotherapy.

A partitioned-survival lifetime model (2025 USD) compared ADT alone with seven intensification strategies across PFS, post-progression, and death, using published survival curves and literature-based ...

In men with hormone-sensitive metachronous oligometastatic prostate cancer, the use of stereotactic body radiotherapy (SBRT) commonly delayed the need for long-term ADT and provided durable disease ...

This medication is a beneficial addition to your prostate cancer treatment plan — but it doesn’t come without risks. Here’s how to stay ahead of potential side effects. If you’ve been diagnosed with ...

Vasomotor symptoms (VMS) including hot flashes are a common complaint among men undergoing androgen deprivation therapy (ADT) for prostate cancer. Although the symptoms are more widely associated with ...

Men with prostate cancer who were treated with the GnRH agonist leuprolide had significantly more coronary artery plaque progression than those receiving the GnRH antagonist relugolix.